MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
9.41
-0.53 (-5.33%)
Oct 16, 2026, 4:00 PM EDT - Market closed
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
48.02M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Werewolf Therapeutics | 21.00M |
| Caribou Biosciences | 10.04M |
| Apollomics | 8.84M |
| Alterity Therapeutics | 2.50M |
| ImageneBio | 800.00K |
| Mereo BioPharma Group | 500.00K |
| iBio, Inc. | 100.00K |
INKT News
- 6 days ago - MiNK Therapeutics management to meet virtually with B. Riley - TheFly
- 6 days ago - MiNK Therapeutics management to meet virtually with B. Riley - TheFly
- 6 days ago - MiNK Therapeutics management to meet virtually with B. Riley - TheFly
- 16 days ago - MiNK Therapeutics to present data on cancer research at SITC 2026 - TheFly
- 16 days ago - MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026 - GlobeNewsWire
- 18 days ago - MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy - TheFly
- 18 days ago - MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy - GlobeNewsWire
- 2 months ago - MiNK Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts